Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Image 1.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930072 | PMC |
| http://dx.doi.org/10.1016/j.jpha.2024.101079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization.
Pharmaceutics
April 2025
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
This study aimed to develop a population pharmacokinetic (PK) model that characterized the plasma concentration-time profiles of the total and unbound pamiparib, a PARP inhibitor, in glioblastoma patients and identified patient factors influencing the PK. The total and unbound pamiparib plasma concentration data were obtained from 41 glioblastoma patients receiving 60 mg of pamiparib twice daily. Nonlinear mixed-effects modeling was performed using Monolix (2024R1) to simultaneously fit the total and unbound drug plasma concentration data.
View Article and Find Full Text PDFDistribution of pamiparib, a novel inhibitor of poly(ADP-ribose)-polymerase (PARP), in tumor tissue analyzed by multimodal imaging.
J Pharm Anal
March 2025
IRCCS Humanitas Research Hospital, Rozzano, 20089, Italy.
Image 1.
View Article and Find Full Text PDFMechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors.
Clin Pharmacol Ther
March 2025
Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, Arizona, USA.
Direct measurement of spatial-temporal drug penetration and exposure in the human central nervous system (CNS) and brain tumors is difficult or infeasible. This study aimed to develop an innovative mechanistic modeling platform for quantitative prediction of spatial pharmacokinetics of systemically administered drugs in the human CNS and brain tumors. A nine-compartment CNS (9-CNS) physiologically-based pharmacokinetic model was developed to account for general anatomical structure and pathophysiological heterogeneity of the human CNS and brain tumors.
View Article and Find Full Text PDF